GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avacta Group PLC (LSE:AVCT) » Definitions » Enterprise Value

Avacta Group (LSE:AVCT) Enterprise Value : £125.45 Mil (As of May. 03, 2025)


View and export this data going back to 2003. Start your Free Trial

What is Avacta Group Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Avacta Group's Enterprise Value is £125.45 Mil. Avacta Group's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was £-13.78 Mil. Therefore, Avacta Group's EV-to-EBIT ratio for today is -9.10.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Avacta Group's Enterprise Value is £125.45 Mil. Avacta Group's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was £-9.85 Mil. Therefore, Avacta Group's EV-to-EBITDA ratio for today is -12.73.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Avacta Group's Enterprise Value is £125.45 Mil. Avacta Group's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was £22.62 Mil. Therefore, Avacta Group's EV-to-Revenue ratio for today is 5.55.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Avacta Group's Enterprise Value is £125.45 Mil. Avacta Group's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was £-20.83 Mil. Therefore, Avacta Group's EV-to-FCF ratio for today is -6.02.


Avacta Group Enterprise Value Historical Data

The historical data trend for Avacta Group's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avacta Group Enterprise Value Chart

Avacta Group Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.82 242.16 296.51 284.86 334.79

Avacta Group Semi-Annual Data
Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 264.78 284.86 293.67 334.79 188.55

Competitive Comparison of Avacta Group's Enterprise Value

For the Biotechnology subindustry, Avacta Group's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avacta Group's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avacta Group's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Avacta Group's Enterprise Value falls into.


;
;

Avacta Group Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Avacta Group's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Avacta Group's Enterprise Value for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avacta Group  (LSE:AVCT) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Avacta Group's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=125.445/-13.779
=-9.10

Avacta Group's current Enterprise Value is £125.45 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Avacta Group's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was £-13.78 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Avacta Group's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=125.445/-9.853
=-12.73

Avacta Group's current Enterprise Value is £125.45 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Avacta Group's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was £-9.85 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Avacta Group's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=125.445/22.619
=5.55

Avacta Group's current Enterprise Value is £125.45 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Avacta Group's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was £22.62 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Avacta Group's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=125.445/-20.833
=-6.02

Avacta Group's current Enterprise Value is £125.45 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Avacta Group's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was £-20.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avacta Group Enterprise Value Related Terms

Thank you for viewing the detailed overview of Avacta Group's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Avacta Group Business Description

Traded in Other Exchanges
Address
Unit 20, Ash Way, Thorp Arch Estate, West Yorkshire, Wetherby, GBR, LS23 7FA
Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.

Avacta Group Headlines

No Headlines